In an elderly patient with chronic constipation, how does senna (sennosides) compare to lactulose and bisacodyl in terms of efficacy, dosing, and safety?

Senna vs. Lactulose vs. Bisacodyl in Geriatric Constipation

For elderly patients with chronic constipation, start with senna at a low dose (8-9 mg daily, not the 1g studied) as first-line therapy, reserve bisacodyl for short-term or rescue use only (≤4 weeks), and use lactulose only after over-the-counter options fail due to its inferior efficacy and problematic side effects in this population. 1

Efficacy Comparison

Senna: The Preferred First-Line Option

• Significantly superior to lactulose in head-to-head trials in geriatric patients: 4.5 vs 2.2 bowel movements per week (p<0.001) 2
• Produces 7.6 more complete spontaneous bowel movements (CSBMs) per week compared to placebo (95% CI 5.90-9.30) 1
• Response rate 5.25 times higher than placebo 1
• More cost-effective: 10.3p per stool vs 39.7p for lactulose 2
• Improves quality of life scores significantly (MD 7.80,95% CI 1.40-14.20) 1

Bisacodyl: Reserve for Short-Term/Rescue Use

• Strongest evidence base (moderate certainty) with robust efficacy: increases CSBMs from 1.1 to 5.2 per week vs 1.9 with placebo (p<0.0001) 1, 3
• However, high adverse event rates limit use: At 10mg, diarrhea occurs in 53.4% vs 1.7% placebo; abdominal pain in 24.7% vs 2.5% 1
• Guidelines explicitly recommend short-term use only (≤4 weeks) or as rescue therapy 1
• Start at 5mg (not the 10mg studied) to minimize side effects 1

Lactulose: Third-Line After OTC Failure

• Conditional recommendation with very low certainty evidence 1
• Guidelines position it specifically for patients who "fail or are intolerant to OTC therapies" 1
• Inferior to senna in geriatric trials: 2.2 bowel movements/week vs 4.5 with senna 2
• Problematic side effects in elderly: bloating and flatulence are dose-dependent and "may limit its use in clinical practice" 1
• Requires higher dosing (15ml twice daily vs senna 10ml once daily) 2

Practical Dosing Algorithm

Step 1: Start with Senna

• Initial dose: 8-9 mg (one tablet) at bedtime 1, 4
• Critical caveat: Trial doses (1g) are much higher than clinical practice; 83% of trial participants reduced their dose 1
• Titrate up slowly if no response after 3-4 days
• Maximum: 15 mL (approximately 17mg sennosides) twice daily 4
• Longer-term use is appropriate despite 4-week trial duration 1

Step 2: If Senna Fails or Not Tolerated

• Consider adding or switching to PEG (polyethylene glycol) - this has a strong recommendation with moderate evidence 1
• PEG has durable response over 6 months and better tolerability profile than lactulose 1

Step 3: Bisacodyl for Acute Relief Only

• 5 mg orally (not 10mg) for short-term use (≤4 weeks) 1
• Onset: 6-12 hours oral; 30-60 minutes rectal suppository (10mg) 1
• Use as rescue therapy in combination with maintenance agents 1

Step 4: Lactulose if OTC Options Fail

• Dosing: 15-30 mL (10-20g) 2-3 times daily 5
• Adjust to produce 2-3 soft stools daily 5
• Warn patients about bloating/flatulence which are dose-dependent 1

Critical Safety Considerations in Geriatrics

Senna Safety Profile

• No severe adverse events reported in trials 1
• Abdominal cramping/pain occurs with higher doses - hence start low 1
• Long-term safety concerns are unfounded: Recent comprehensive review found no evidence of colonic damage, neural injury, or cancer risk with chronic use 6
• Avoid in pregnancy (theoretical genotoxic concerns in animals) 1

Bisacodyl Contraindications

• Ileus, intestinal obstruction, severe dehydration, acute inflammatory bowel conditions 1
• Most adverse events occur in first week 1
• Antibiotic use may reduce efficacy (affects bacterial conversion to active metabolite) 1

Lactulose Specific Issues in Elderly

• Bloating/flatulence particularly problematic in frail elderly 1
• May take 24-48 hours or longer for effect 5
• Higher volume requirements may be difficult for elderly with swallowing issues

Common Pitfalls to Avoid

1. Don't start with lactulose first - guidelines clearly position it after OTC failure, and geriatric trials show senna superiority 1, 2

2. Don't use bisacodyl long-term - despite its efficacy, the strong guideline recommendation limits it to ≤4 weeks or rescue use 1

3. Don't use trial doses of senna - the 1g studied is 10-12 times higher than standard tablets; start with 8-9mg 1, 4

4. Don't fear long-term senna use - outdated concerns about colonic damage are not evidence-based 6

5. Don't forget PEG - if senna fails, PEG (not lactulose) should be next consideration per guidelines 1

Evidence Quality Context

The 2023 AGA-ACG guidelines 1 provide the framework: bisacodyl has moderate certainty evidence with a strong recommendation for short-term use, senna has low certainty evidence with a conditional recommendation, and lactulose has very low certainty evidence with a conditional recommendation only after OTC failure. However, geriatric-specific trials consistently favor senna over lactulose 2, 7, 8, making it the practical first choice in this population despite lower overall evidence quality.